Nuvectis Pharma (NASDAQ:NVCT) Trading 6.2% Higher – What’s Next?

Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) were up 6.2% during trading on Tuesday . The company traded as high as $19.68 and last traded at $20.2650. 27,455 shares were traded during mid-day trading, a decline of 83% from the average session volume of 163,211 shares. The stock had previously closed at $19.08.

Analyst Ratings Changes

Several research firms have commented on NVCT. Roth Capital raised their price objective on Nuvectis Pharma from $20.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, July 6th. UBS Group set a $33.00 target price on Nuvectis Pharma in a report on Monday, July 6th. Wall Street Zen upgraded Nuvectis Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings lowered shares of Nuvectis Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. Finally, HC Wainwright upped their target price on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $35.00.

Nuvectis Pharma Stock Performance

The stock’s fifty day simple moving average is $18.54 and its two-hundred day simple moving average is $12.37. The company has a market capitalization of $653.26 million, a price-to-earnings ratio of -15.45 and a beta of -0.26.

Nuvectis Pharma (NASDAQ:NVCT) last issued its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). On average, equities analysts anticipate that Nuvectis Pharma, Inc. will post -0.98 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Ron Bentsur acquired 12,500 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were purchased at an average cost of $20.00 per share, with a total value of $250,000.00. Following the completion of the transaction, the chief executive officer owned 3,688,424 shares of the company’s stock, valued at approximately $73,768,480. This trade represents a 0.34% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Marlio Charles Mosseri bought 50,000 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were bought at an average cost of $18.32 per share, with a total value of $916,000.00. Following the purchase, the insider directly owned 3,186,576 shares in the company, valued at approximately $58,378,072.32. This trade represents a 1.59% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 28.55% of the company’s stock.

Institutional Trading of Nuvectis Pharma

Several large investors have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC acquired a new stake in shares of Nuvectis Pharma in the second quarter worth about $735,600,000. Bank of America Corp DE acquired a new stake in shares of Nuvectis Pharma in the second quarter valued at about $218,000. Legal & General Group Plc acquired a new position in shares of Nuvectis Pharma during the 2nd quarter worth about $31,000. BlackRock Inc. acquired a new stake in Nuvectis Pharma in the 2nd quarter valued at approximately $18,414,000. Finally, Deutsche Bank AG bought a new stake in shares of Nuvectis Pharma in the second quarter valued at approximately $310,000. 96.77% of the stock is owned by institutional investors.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.